NanoEcho AB (publ) (STO:NANECH)
0.0422
+0.0022 (5.50%)
At close: Jun 10, 2026
NanoEcho AB Earnings Call Transcripts
Fiscal Year 2024
-
Transitioned to clinical phase after completing product development and regulatory milestones. Net loss increased to SEK 8.7 million with no revenue, but a successful rights issue secured 12 months of capital for clinical trials. Market approval is targeted for H2 2027.